Kingray Capital News Today

The Series D+ round was led by GTJA Investment Group and Beijing-based state capital investor Kingray Capital.

Biopharmaceutical firm Jiangsu Atom Bioscience and Pharmaceutical has bagged 600 million yuan ($82.8 million) in a Series D funding round.

Previously, the Quzhou-headquartered firm secured an undisclosed sum in February, joined by China Renaissance, and CICC Capital, among others.

TopOlefin Technology has raked in 1 billion yuan ($138.9 million) in a Series B round led by local PE investment firms Kingray Capital and Raystone Capital. 

The round was led by PE investment firm Kingray Capital and Gree Financial Investment.

Epigenic Therapeutics has secured $20m in Series Angel and Pre-A funding to proceed with next-generation gene editing therapy.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Press release content from PR Newswire. The AP news staff was not involved in its creation.

SHANGHAI, Aug. 6, 2022 /PRNewswire/ -- Epigenic Therapeutics Co., Ltd., a frontier biotechnology company dedicated to developing next generation gene

/PRNewswire/ -- Epigenic Therapeutics Co., Ltd., a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing...